Author

B. Haagmans

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Assay:proteomics· 5 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:imaging· 2 Organism:non-human primate· 2

Frequent Co-Authors

B. Rockx· 4 shared A. Z. Mykytyn· 3 shared M. Koopmans· 3 shared M. M. Lamers· 3 shared N. Okba· 3 shared R. Fouchier· 3 shared C. GeurtsvanKessel· 2 shared C. Wang· 2 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

B. Rockx

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters

M. Rissmann, D. Noack, D. van Riel, K. S. Schmitz, R. D. de Vries, P. van Run, M. M. Lamers, C. GeurtsvanKessel, M. Koopmans, R. Fouchier, T. Kuiken, B. Haagmans, B. Rockx

This study inoculates Syrian golden hamsters with SARS-CoV-2 Omicron BA.1 to compare its pathogenicity and viral shedding to Delta, finding reduced clinical signs and viral shedding but still pneumonia, with pre-existing immunity offering protection.

bioRxiv · Mar 15, 2022Microbiology

Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants

A. Z. Mykytyn, M. Rissmann, A. Kok, M. Rosu, D. Schipper, T. I. Breugem, P. B. van den Doel, F. Chandler, T. Bestebroer, M. de Wit, M. E. van Royen, R. Molenkamp, B. Oude Munnink, R. D. de Vries, C. GeurtsvanKessel, , B. Haagmans

This study compares the antigenic differences between SARS-CoV-2 Omicron BA.1 and BA.2 variants using antigenic cartography and hamster sera, finding they are distinct antigenic outliers.

bioRxiv · Feb 23, 2022 · PreprintMicrobiology

Glycosylated extracellular mucin domains protect against SARS CoV-2 infection at the respiratory surface

M. Chatterjee, L. Z. X. Huang, A. Z. Mykytyn, C. Wang, M. M. Lamers, B. Westendorp, R. W. Wubbolts, J. P. M. v. Putten, B. J. Bosch, B. Haagmans, K. Strijbis

This study shows that glycosylated mucin domains on respiratory epithelial cells restrict SARS-CoV-2 infection by reducing viral entry.

bioRxiv · Oct 29, 2021Microbiology

3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements

I. Tomris, K. M. Bouwman, Y. Adolfs, D. Noack, R. van der Woude, S. Herfst, G.-J. Boons, B. Haagmans, R. J. Pasterkamp, B. Rockx, R. P. de Vries

The paper uses 3D visualization to show that SARS-CoV-2 infection in Syrian hamster lungs occurs only where ACE2 and TMPRSS2 co-localize.

bioRxiv · Mar 24, 2021Microbiology

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A. Tscherne, J. H. Schwarz, C. Rohde, A. Kupke, G. Kalodimou, L. Limpinsel, N. M. A. Okba, B. Bosnjak, I. Sandrock, S. Halwe, L. Sauerhering, K. Printz, L. Nan, E. Duell, S. Jany, , A. Volz

This paper describes the preclinical evaluation of MVA-SARS-2-S, a vector vaccine against SARS-CoV-2, showing it induces immune responses and protects mice from infection.

bioRxiv · Jan 9, 2021Microbiology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

bioRxiv · Nov 7, 2020Immunology

Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein

C. Wang, R. van Haperen, J. Gutierrez-Alvarez, W. Li, N. Okba, I. Albulescu, I. Widjaja, B. van Dieren, R. Fernandez-Delgado, I. Sola, D. Hurdiss, O. Daramola, F. Grosveld, F. van Kuppeveld, B. Haagmans, , B.-J. Bosch

This study isolates two cross-reactive monoclonal antibodies against multiple Betacoronaviruses, identifying a conserved vulnerable site on the spike protein.

bioRxiv · Oct 20, 2020 · PreprintMicrobiology

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

P. Brouwer, T. Caniels, K. van Straten, J. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, N. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. van Haaren, D. Guerra, J. Burger, E. Schermer, , M. van Gils

This study isolates potent neutralizing antibodies from COVID-19 patients that target multiple sites on the SARS-CoV-2 spike protein, offering insights for vaccine design and therapeutic development.

bioRxiv · May 12, 2020Microbiology

Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model

B. Rockx, T. Kuiken, S. Herfst, T. Bestebroer, M. Lamers, D. de Meulder, G. van Amerongen, J. van de Brand, N. Okba, D. Schipper, P. van Run, L. Leijten, E. Verschoor, B. Verstrepen, J. Langermans, , B. Haagmans

This study compares the pathogenesis of SARS-CoV-2, MERS-CoV, and SARS-CoV in non-human primates, showing SARS-CoV-2 causes a COVID-19-like disease with prolonged viral excretion without clinical signs.

bioRxiv · Mar 17, 2020Microbiology